About Ensysce
Ensysce is a publicly listed company based in Houston (United States) founded in 2008. Drug delivery solutions via single-walled carbon nanotubes are offered. Ensysce has raised $2.5 million across 9 funding rounds from investors including HHS, SBIR and Texas Emerging Technology Fund. The company has 9 employees. Ensysce has completed 1 acquisition, including Signature Therapeutics. Its chief executive, as recorded, is Lynn Kirkpatrick. Ensysce offers products and services including TAAP™ and MPAR®. Its focus areas include Life Sciences, Toxicology and Drugs. Its legal entity is Signature RX Inc. Its competitors include PharmaJet, Suono Bio and Renovis; 3 of its 3 listed competitors have raised funding.
Company details
Ensysce was founded in 2008 and is based in Houston, United States. Operations focus on the biotechnology sector, where single-walled carbon nanotubes are developed for cancer treatment applications. These nanotubes enable delivery of active agents, including small interfering RNA, cancer drugs, and alpha-emitting radiation, into tumor cells while bypassing natural barriers and minimizing exposure to healthy tissues.
- Headquarters Houston, United States
- Employees 9
- Stage Public
- SectorsHealthcare
- Website ensysce.com
- Social LinkedIn X
- Legal Name Ensysce Biosciences, Inc.
- Annual Revenue$5.07 M (USD)-2.75as on Dec 31, 2025
- Net Profit-$10.18 M (USD)-27.4as on Dec 31, 2025
- EBITDA-$10.23 M (USD)-52.07as on Dec 31, 2025
- Total Equity Funding$2.5M (USD)
in 9 rounds
- Latest Funding Round$4M (USD), Post-IPO
Nov 2025
- InvestorsHHS
& 2 more
- Employee Count9
- Investments & Acquisitions
Products & Services of Ensysce
Ensysce offers a comprehensive portfolio of products and services, including TAAP™ and MPAR®.
Reduces drug abuse risks through novel platform for oral prescriptions
Prevents opioid overdose with multi-pill resistant features
Funding Insights of Ensysce
Ensysce has successfully raised a total of $2.5M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.5M
- Total Rounds 9
- Last Round Post-IPO — $4M
- First Round $1.5M
(Jun 2010)
- Investors Count 3
All 9 funding rounds of Ensysce with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2025 | $4M | Post-IPO | – | – | – |
| Feb 2023 | $2.82M | Post-IPO | – | – | – |
| Jun 2022 | $8M | Post-IPO | – | – | – |
| Nov 2021 | $15M | Post-IPO | – | – | – |
| Jan 2021 | $60M | Post-IPO | – | – | – |
| Sep 2012 | $300,000 | Grant | – | – | |
| Sep 2012 | $298,072 | Grant | – | – | |
| Jun 2012 | $1M | Seed | – | – | |
| Jun 2010 | $1.5M | Seed | – | – |
3 investors in total: 3 institutional.
Investors in Ensysce
Ensysce has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, SBIR and Texas Emerging Technology Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| emergingtechfund.com | ||||
Federal innovation and scientific achievement services are provided. | 1982 | sbir.gov | Lithia Springs, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Ensysce
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ensysce
18 people are tracked at Ensysce (8 in leadership, 10 in board & advisors); the tracked headcount is 9.
| Name | Role | Group |
|---|---|---|
Lynn Kirkpatrick | CEO | Leadership |
Dave Humphrey | Chief Financial Officer | Leadership |
D. Lynn Kirkpatrick | CEO | Leadership |
Geoff Birkett | Chief Commercial Officer | Leadership |
Linda Pestano | Chief Development Officer | Leadership |
William Schmidt | Chief Medical Officer. | Leadership |
Lindsey Millard | Director Of Translational Sciences | Leadership |
Jeffrey Millard | COO | Leadership |
Bob Gower | Director | Board & advisors |
William Chang | Director | Board & advisors |
Steve Martin | Director | Board & advisors |
Andrew Benton | Director | Board & advisors |
Richard Dart | Scientific Advisor | Board & advisors |
Lynn Webster | Scientific Advisor | Board & advisors |
Curtis Rosebraugh | Director | Board & advisors |
Adam Levin | Director | Board & advisors |
Lee Rauch | Director | Board & advisors |
Jeffrey Gudin | Scientific Advisor | Board & advisors |
Complete people profiles for Ensysce
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Ensysce
Ensysce is a publicly listed company on the NASDAQ with ticker symbol ENSC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Feb 2018
- Listed onNASDAQ: ENSC
- Listed entityEnsysce Biosciences, Inc.
- Exchange sectorHealth technology
- ISINUS2936025046
- Share price$0.57 (+2.99% on the day) · 2026-10-13
- Market capitalisation$11.1M
- EPS (diluted, trailing year)$-2.76
- Volume (last session)1,218,489
Financials of Ensysce
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $5.1M | -$10.2M | -$10.2M |
| 2024 | $5.2M | -$8.0M | -$6.7M |
| 2023 | $2.2M | -$10.6M | -$10.7M |
| 2022 | $2.5M | -$24.2M | -$24.2M |
| 2021 | $3.5M | -$29.1M | -$19.9M |
Detailed financial statements for Ensysce
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ensysce
Ensysce has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Signature Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Prodrug formulations are developed to prevent prescription medication misuse. | signaturerx.com | San Carlos, United States | 2004 | Jan 2015 | •••• |
Complete acquisition details for Ensysce
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Ensysce
5 dated milestones of Ensysce across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Ensysce is founded.
- Funding First funding round of $1.5M.
- Acquisition Acquires Signature Therapeutics.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $4.0M.
Competitors of Ensysce
Ensysce has 3 listed competitors in our database, 3 of them funded. They include PharmaJet, Suono Bio and Renovis.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pharmajet.com | 2005 | Golden, United States | $59.4M | 15 | Provider of needle-free injection technology | |
| suonobio.com | 2015 | Cambridge, United States | $12.68M | Developer of technology to enable ultra-rapid delivery of therapeutics to the gastrointestinal tract | ||
| renovis.com | 2000 | San Francisco, United States | $45M | 368 | Drugs for neurological diseases are discovered and developed. |
Detailed competitors of Ensysce
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ensysce
The website of Ensysce (ensysce.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▼ 4.3% vs previous month
Top companies in Toxicology
3 companies that operate in the same segment as Ensysce (Toxicology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutic solutions for food allergies are developed via antibody platforms. | 2019 | San Francisco, California, United States | USD 75 M | |||
Therapeutics for substance use disorders, including opioid-related conditions, are developed. | 2020 | Oakland, California, United States | USD 70 M | |||
Instruments for rapid human DNA identification are developed. | 2006 | Pleasanton, California, United States | USD 92.06 M | USD 22.5 B | 78 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ensysce
Complete news archive for Ensysce
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ensysce
Ensysce was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Ensysce is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Lynn Kirkpatrick is the CEO of Ensysce, as recorded in our data.
Ensysce is a funded company, having raised a total of $2.5M across 9 funding rounds to date. The company's 1st funding round was a Seed of $1.5M, raised on Jun 2010.
Ensysce has 9 employees.
Annual revenue of Ensysce is $5.07M as on Dec 31, 2025.
Ensysce was founded in 2008 and is based in Houston, United States. Operations focus on the biotechnology sector, where single-walled carbon nanotubes are developed for cancer treatment applications. These nanotubes enable delivery of active agents, including small interfering RNA, cancer drugs, and alpha-emitting radiation, into tumor cells while bypassing natural barriers and minimizing exposure to healthy tissues.
Ensysce offers TAAP™ and MPAR®.
Yes, Ensysce is publicly traded on NASDAQ under the ticker symbol ENSC.
Ensysce has made 1 acquisition, including Signature Therapeutics.